文献速递临床试验与 GCP组学、生物样本库与精准医学

阴道补充乳杆菌逆转多囊卵巢综合征患者体外受精-冻融胚胎移植后下生殖道菌群失调并改善围产结局的多中心随机对照试验研究方案

Effect of transvaginal Lactobacillus supplementation on reversing lower genital tract dysbiosis and improving perinatal outcomes in PCOS patients after IVF-FET: a study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2023-12-21

该研究方案为在中国开展的多中心、开放标签、随机对照试验,拟纳入接受体外受精-冻融胚胎移植的多囊卵巢综合征患者。干预组在胚胎移植前连续10天经阴道给予活乳杆菌胶囊,对照组接受标准个体化护理。主要结局为临床妊娠率、着床率和活产率,计划招募300例参与者。

要点

  • 多中心开放标签随机对照试验,比较经阴道乳杆菌补充与标准个体化护理。
  • 主要结局为临床妊娠率、着床率和活产率。
  • 计划招募300例,260例可提供95%把握度检出临床妊娠率提高20%。

核心结论

  • 这是首个旨在评估经阴道补充乳杆菌恢复下生殖道菌群并改善多囊卵巢综合征患者体外受精-冻融胚胎移植后围产结局的大型多中心随机对照试验。

研究设计与样本

  • 多中心、开放标签、随机对照试验方案,在中国开展,纳入接受体外受精-冻融胚胎移植的多囊卵巢综合征患者,按1:1比例电子随机分配至干预组或对照组。

主要发现

  • 干预组在胚胎移植前连续10天经阴道给予活乳杆菌胶囊,对照组接受标准个体化护理。主要结局为临床妊娠率、着床率和活产率。将采用16S rRNA测序和液相色谱-质谱联用评估干预前后下生殖道微生物组和全身代谢组学。

关键数值与推荐

  • 260例样本可提供95%把握度检出临床妊娠率提高20%(α=0.025,单侧检验,脱落率15%)。共计划招募300例参与者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Significant lower genital tract (LGT) dysbiosis and an associated lower rate of clinical pregnancy after in vitro fertilization-frozen embryo transfer (IVF-FET) among polycystic ovary syndrome (PCOS) patients have been previously reported by our group. We aimed to assess whether transvaginal Lactobacillus supplementation can reverse LGT dysbiosis and further improve perinatal outcomes in PCOS patients after IVF-FET. METHODS/DESIGN: This is a protocol for a multicenter, open-label, randomized controlled trial in China. Women diagnosed with PCOS who are undergoing IVF-FET treatment will be recruited. Allocation to the intervention/control arms at a ratio of 1:1 will be executed by an electronic randomization system. Participants in the intervention arm will receive the live Lactobacillus capsule vaginally for 10 consecutive days before embryo transfer, while those in the control arm will receive standard individualized care. The primary outcomes will be the clinical pregnancy rate, implantation rate, and live birth rate. 16S rRNA sequencing and liquid chromatography-mass spectrometry will be conducted to evaluate the LGT microbiome and systemic metabonomics before and after the intervention. A sample of 260 participants will provide 95% power to detect a 20% increase in the rate of clinical pregnancy (α = 0.025, one-tailed test, 15% dropout rate). A total of 300 participants will be recruited. DISCUSSION: This is the first large and multicenter randomized controlled trial aimed at assessing the efficacy of transvaginal Lactobacillus supplementation on restoring the LGT microbiome and improving perinatal outcomes in PCOS patients after IVF-FET. This pragmatic trial is promising for increasing the rates of clinical pregnancy and live birth in PCOS patients after IVF-FET. ETHICS AND DISSEMINATION: Ethical review approval was obtained from the Medical Research Ethics Committees of the International Peace Maternity and Child Health Hospital of Shanghai Jiao Tong University (15 October 2020, GKLW 2020-29). To maximize dissemination, these findings will be reported in open access publications in journals with high impact, and oral and poster conference presentations will be performed. TRIAL REGISTRATION: ChiCTR ChiCTR2000036460. Registered on 13 September 2020, https://www.chictr.org.cn/showproj.html?proj=59549 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen H, Tu Y, Zhang C, et al. Effect of transvaginal Lactobacillus supplementation on reversing lower genital tract dysbiosis and improving perinatal outcomes in PCOS patients after IVF-FET: a study protocol for a multicenter randomized controlled trial. Trials. 2023. PMID: 38129882. doi:10.1186/s13063-023-07825-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。